Cerebrolysin: A Peptide Mixture Explained

Cerebrolysin is not a single peptide. It is a mixture of low-molecular-weight peptides and free amino acids produced by controlled enzymatic breakdown of proteins from porcine (pig) brain. It is used as a medicine in Russia, China and a number of other countries in Asia and Eastern Europe, and it is not approved by the FDA in the United States.

Because it is a mixture, almost everything that is simple for a defined peptide, such as a sequence, a molecular formula or a CAS number, has no single answer for Cerebrolysin. This profile explains what the preparation contains, how researchers characterize it, what it has been studied in and what that means for handling it in the lab.

Cerebrolysin at a glance

Catalog material is described on the Cerebrolysin page.

What "a peptide mixture" means

A defined synthetic peptide such as DSIP has one sequence, one molecular formula and one expected mass. A quality report checks that the main component has that mass and measures how much of the material it accounts for.

Cerebrolysin starts from the other end. Brain proteins are digested with proteases, and the digest is processed to keep the low-molecular-weight fraction. What remains is a population of short peptide fragments from many parent proteins, together with the free amino acids that proteolysis releases. It is closer to a standardized biological extract than to a synthetic peptide. The difference between the two categories is covered in what peptides are.

Descriptions of the ratio between the peptide fraction and the free amino acid fraction are not consistent across published sources. The 2023 Cochrane review describes the preparation as roughly 80% peptides and 20% free amino acids, while other descriptions give a much smaller peptide share. The exact figure depends on whether the measure is weight, nitrogen content or molar amount, and we do not quote one here as definitive.

How the composition has been analyzed

Two kinds of work show what the mixture contains.

Peptidomics. A 2019 study by Gromova and colleagues analyzed the light peptide fraction of Cerebrolysin by high-resolution mass spectrometry with orbital ion traps and de novo sequencing. They reported sequences for 14,635 peptides, mapping to 1,643 porcine neuronal proteins. Among them they identified Leu- and Met-enkephalin and fragments of orexin, neuropeptide VF, galanin and nerve growth factor. The study was published in Russian with an English abstract.

Fingerprinting against similar products. A number of other brain-derived peptide preparations are sold in various countries. In 2024, Seidl and Aigner at Paracelsus Medical University in Salzburg compared Cerebrolysin with eleven such products sold under other names in various countries. They used reversed-phase HPLC to compare peptide fingerprints and a PC12 cell assay to compare activity. The authors reported that the peptide composition of the other products differed substantially from Cerebrolysin.

The practical lesson is that "brain peptide preparation" is not one substance. Two products made from the same tissue by different processes can have different peptide profiles, and a fingerprint is the only way to compare them.

What Cerebrolysin has been studied in

The research literature on Cerebrolysin is large, and it divides into laboratory work and human trials.

Cell culture. The 2024 Salzburg study used PC12 cells, a rat pheochromocytoma line widely used as a model of neuronal differentiation. The cells carried a reporter in which enhanced green fluorescent protein was fused to neurofilament-L, so neuronal differentiation could be read by flow cytometry. The same study included an amino acid solution matched to Cerebrolysin's amino acid component as a control, to separate what the peptides do from what the free amino acids do.

Mechanism. Because the peptidome includes fragments of known neuropeptides and growth factors, most mechanistic work frames Cerebrolysin as acting through neurotrophic-like signaling. That framing comes from the composition and from cell and animal studies; it has not been traced to a single active sequence.

Animal models. Cerebrolysin has been examined in rodent models of ischemic injury, traumatic injury and neurodegeneration. These are research models, and findings in them do not establish anything about people.

Human trials. Randomized trials have been run in several countries, mostly in acute ischemic stroke. The Cochrane review of 2023 (Ziganshina and colleagues) assessed these trials, looking at measures including all-cause death and serious adverse events. Readers who need the findings should go to the review itself; this profile does not summarize them.

Related brain-derived preparations

Cerebrolysin is the best-known member of a small class of tissue-derived peptide preparations. The Cochrane review describes a second, Cortexin, as a Russian-made mixture of oligopeptides and short-chain peptides with amino acids, used in Russia and the Commonwealth of Independent States. It is made from a different source and by a different process, and the two are not interchangeable.

Short peptides isolated from, or modeled on, animal tissue extracts have a longer history in Russian research. Some later work moved from extracts to single synthetic sequences: Epithalon, for example, is a defined tetrapeptide designed from the composition of a pineal extract. Selank and Semax, two synthetic heptapeptides from Moscow's Institute of Molecular Genetics, are other examples of defined sequences from the same research tradition. For a lab, the useful distinction is simple: an extract is characterized by a fingerprint, and a synthetic sequence by its mass and purity.

Regulatory status by country

The manufacturer is based in Austria. Authorization is country by country, and the list changes over time, so a national medicines register is the only reliable source for any one country. None of this affects the status of research material: research-grade Cerebrolysin is supplied for in-vitro laboratory work only, as described on our research use page.

Handling a mixture in the lab

Anhydrolabs supplies Cerebrolysin as a lyophilized powder in vacuum-sealed vials, and also as 10-vial kits. Working with a mixture changes a few routine steps.

Quality documents look different. For a single peptide, a certificate reports purity as the area of the principal peak in an HPLC trace. For a mixture there is no single main component to measure, so identity is shown as a fingerprint: a characteristic pattern of many signals that matches a reference. Mass spectrometry confirms that the masses present are in the expected low-molecular-weight range. Our guide to reading a certificate of analysis explains the standard sections, and peptide purity explains what an HPLC area figure means for a single peptide.

Dissolving. The components are short and mostly hydrophilic, and the material dissolves in water or a neutral buffer. Stock solutions are described by concentration (for example, mg/mL of lyophilized solid), not by molarity, because a mixture has no single molecular weight.

Controls. Because free amino acids make up part of the material, an amino acid control matched to the composition is useful in cell work, as the Salzburg study did. Without it, it is hard to tell a peptide-specific signal from a nutritional one in culture.

Stability. Many different peptides mean many different degradation routes: oxidation of methionine and tryptophan, deamidation of asparagine and glutamine, and further proteolysis by any contaminating enzyme. Keep lyophilized vials cold (-20 °C), dry and dark. After dissolving, split the solution into single-use aliquots and freeze them, and use sterile technique so microbial proteases do not alter the profile. See how to store peptides for the general rules.

Batch comparison. If a study runs across several lots, keep the certificate for each and compare fingerprints. A change in the pattern is more informative than a single purity figure would be.

How it compares with defined peptides